Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Other Accumulated Expenses (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Other Accumulated Expenses for 6 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 24.53% to $10.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.1 million, a 24.53% increase, with the full-year FY2025 number at $10.1 million, up 24.53% from a year prior.
  • Other Accumulated Expenses was $10.1 million for Q4 2025 at PROCEPT BioRobotics, up from $8.2 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $10.1 million in Q4 2025 to a low of $2.8 million in Q3 2021.
  • A 5-year average of $7.1 million and a median of $7.8 million in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 133.08% in 2021, then decreased 15.4% in 2023.
  • PROCEPT BioRobotics' Other Accumulated Expenses stood at $4.6 million in 2021, then surged by 62.07% to $7.5 million in 2022, then fell by 15.4% to $6.3 million in 2023, then rose by 28.03% to $8.1 million in 2024, then grew by 24.53% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Other Accumulated Expenses are $10.1 million (Q4 2025), $8.2 million (Q3 2025), and $9.7 million (Q2 2025).